This article discusses the most prevalent risk factors, as well as the clinical signs and symptoms, associated with RA.
DMARDs alone or with methotrexate and tofacitinib plus methotrexate improved disease activity and remission rates in patients with RA who have not responded to previous biologic therapy.
Patients with RA suffering from S. aureus infection have more complications and higher mortality rates than patients without RA.
EULAR recommendations were updated for rheumatoid arthritis management to include new guidelines on starting effective therapy in patients early.
Patients with early RA treated with very low-dose glucocorticoids over 7 years experienced similar toxicity as patients who were not treated with glucocorticoids.
Preclinical alterations in levels of soluble mediators may predict transition to SLE for unaffected relatives of patients with SLE.
A phase 3, double-blind, randomized placebo-controlled study was conducted in 551 patients with active RA who received secukinumab, abatacept, or placebo.
This study included phase 3 trial in patients taking baricitinib, adalimumab, or placebo in addition to methotrexate background therapy.
Consuming adequate amounts of the right nutrients can help relieve symptoms and improve outcomes in patients with systemic lupus erythematosus.
No evidence was found of a higher cardiovascular risk among rheumatoid arthritis patients who switched from a different biologic drug or tofacitinib to tocilizumab vs to a tumor necrosis factor inhibitor.
Pfizer has announced top-line results from its Phase 3B/4 study comparing treatment with Xeljanz to adalimumab in patients with moderate to severe rheumatoid arthritis.
Clinical Pain Advisor Articles
- Transcranial Random Noise Stimulation Effective on Multiple Fibromyalgia-Associated Symptoms
- Comparing Dry Needling, Cortisone for Greater Trochanteric Pain Syndrome
- Vestibular Rehabilitation an Effective Treatment for Vestibular Migraine
- Secondary Hyperalgesia Mediated by Nociceptive and Other Sensory Pathways
- Naloxone: Policies and Access